@article{JTD24451,
author = {Joan Fledelius},
title = {Editorial on “What FDG-PET response-assessment method best predicts survival after curative-intent chemoradiation in non-small cell lung cancer (NSCLC): EORTC, PERCIST, Peter Mac or Deauville criteria?”},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 33},
year = {2018},
keywords = {},
abstract = {The treatment of non-small cell lung cancer (NSCLC) is fortunately an expanding field. Many new treatment regimens are emerging, with second, third, and fourth line therapies. This inadvertently results in a need for a reliable, early evaluation of the treatment response, during or at the end of treatment, enabling a more personalized treatment planning. Treatment response with FDG-PET/CT is an excellent candidate since the metabolic response evaluated with this modality precedes the anatomical response traditionally measured with CT scans and has been shown to be a promising tool in NSCLC (1-4). The variation in how to measure and report a response with FDG-PET/CT is large, rendering the comparison of studies on this subject very difficult.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24451}
}